Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Harding Loevner International Equity ADR composite fell 7.9%, gross, behind the 7.5% decline of the MSCI ACWI ex US Index.
For Q4 2024, the Harding Loevner International Equit composite fell 8.6% (gross) behind the 7.5% decline of the MSCI ACWI ex ...
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback